Modifications of the radiosensitivity of a renal cancer cell line as a consequence of stable TIMP-1 overexpression

A Smyth1, H M Reid, A H Baker

  • 1Cancer & Ageing Research Group, School of Biomedical Sciences, University of Ulster, County Londonderry, Northern Ireland.

Abstract

Insights

Overexpressing tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in renal carcinoma cells enhances DNA damage and cell killing from gamma radiation. This overexpression also impacts matrix metalloproteinase (MMP-2 and MMP-9) activity, showing a dual role in cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Radiation Biology

Background:

  • Matrix metalloproteinases (MMPs) play a role in cancer progression and metastasis.
  • Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a key regulator of MMP activity.
  • The role of TIMP-1 in radioresistance of renal carcinoma is not fully understood.

Purpose of the Study:

  • To investigate the effect of stable TIMP-1 overexpression on DNA damage and cell killing in renal carcinoma cells after gamma-radiation.
  • To determine if TIMP-1 overexpression interferes with the activation of matrix metalloproteinase-2 (MMP-2) and MMP-9.
  • To analyze the impact on cell cycle progression and phenotypic alterations.

Main Methods:

  • Stable transfection of Caki-1 renal carcinoma cells with TIMP-1 cDNA.
  • Assessment of TIMP-1 expression using RT-PCR and Western blot.
  • Irradiation of cells with low-dose gamma radiation (0-10 Gy).
  • Evaluation of DNA damage via Alkaline Comet Assay.
  • Determination of cell survival using clonogenic assays.
  • Analysis of cell cycle distribution by FACS.
  • Measurement of MMP-2 and MMP-9 activity using gelatin zymography.

Main Results:

  • TIMP-1 overexpression significantly increased DNA damage (higher tail moment) and radiosensitivity (decreased survival fraction) in Caki-1 cells post-irradiation.
  • Elevated TIMP-1 levels correlated with increased G2/M phase cell cycle arrest and phenotypic alterations.
  • TIMP-1 overexpression differentially affected MMP-2 and MMP-9 activity, with a marked decrease in MMP-2 and variable changes in MMP-9 levels.

Conclusions:

  • Stable TIMP-1 overexpression acts as a radiosensitizing agent in renal carcinoma cells.
  • TIMP-1 overexpression influences MMP-2 and MMP-9 activity, suggesting a complex regulatory role.
  • These findings highlight a dual role for TIMP-1 in modulating radiation response and protease activity in cancer.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...